{"entity":{"id":"peter-odwyer","kind":"person","name":"Peter J. O'Dwyer","aka":[],"tldr":"Peter O'Dwyer is a GI oncologist who co-leads ECOG-ACRIN, one of the NCI's national trial networks.","summary":"Peter O'Dwyer is Group Co-Chair of the ECOG-ACRIN Cancer Research Group and Professor of Medicine at the University of Pennsylvania, within the Abramson Cancer Center. A gastrointestinal medical oncologist with a background in pharmacology and early drug development, he co-chairs ECOG-ACRIN with Mitchell Schnall and directs the Penn Developmental Therapeutics Program. His papers include the Eastern Cooperative Oncology Group study E3200 of bevacizumab combined with FOLFOX4 for previously treated metastatic colorectal cancer and a New England Journal of Medicine review of the status of etoposide as an active anticancer drug. His work spans colorectal cancer, pancreatic ductal adenocarcinoma and cooperative group trials.","asOf":"2026-09-08","links":[{"label":"ECOG-ACRIN","url":"https://ecog-acrin.org"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=O'Dwyer%20PJ%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Peter%20J.%20O'Dwyer"}],"tags":[],"related":[],"cancers":["colorectal","pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["ecog-acrin"],"institutions":["penn-abramson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Group Co-Chair, ECOG-ACRIN Cancer Research Group; Professor of Medicine, University of Pennsylvania","institutionId":"ecog-acrin","specialisms":["Gastrointestinal oncology","Drug development","Cooperative group trials"],"profiles":[{"label":"ECOG-ACRIN","url":"https://ecog-acrin.org"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=O'Dwyer%20PJ%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Peter%20J.%20O'Dwyer"}],"papers":[{"title":"Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200","journal":"Journal of Clinical Oncology","year":2023,"url":"https://doi.org/10.1200/JCO.22.02761","doi":"10.1200/JCO.22.02761"},{"title":"Etoposide (VP-16-213). Current status of an active anticancer drug","journal":"New England Journal of Medicine","year":1985,"url":"https://doi.org/10.1056/NEJM198503143121106","doi":"10.1056/NEJM198503143121106"}]},"route":"/people/peter-odwyer/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"company":[{"id":"ecog-acrin","kind":"company","name":"ECOG-ACRIN Cancer Research Group","route":"/companies/ecog-acrin/"}],"institution":[{"id":"penn-abramson","kind":"institution","name":"Abramson Cancer Center, University of Pennsylvania","route":"/institutions/penn-abramson/"}],"trial":[{"id":"nci-match","kind":"trial","name":"NCI-MATCH (EAY131)","route":"/trials/nci-match/"}]}}